Biotech | March 06, 2022
Aquestive Therapeutics and Haisco Pharmaceutical partner for riluzole in China.
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
This policy will ensure multi-disciplinary collaboration, promote start-up culture and develop an innovation-led ecosystem at medical institutes across the country
Circular revenues already at 16% of sales, driven by healthcare informatics and services to enhance medical equipment uptime and utilization, system and software upgrades for enhanced functionality and extended lifetime and reusing refurbished parts and systems
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
Subscribe To Our Newsletter & Stay Updated
